Thinly traded nano-cap stock, Galmed Pharmaceuticals $GLMD, boosted by current NASH Stocks rally, got more support after it announced it entered in an agreement with the UC-San Diego School of Medicine to conduct a Phase ½ study, ARTISAN, intended to cure Aramchol in a juvenile population with non-alcoholic fatty liver disease (NAFLD). The study would commence from H1 2017. Since the disease affects about 5% of Americans, NASH treatment makers have got in a horse race to bring their product first in to the market. NASH stock recently received a boost after Allergan $AGN acquired Tobira Therapeutics $TBRA with a generous offer. I had initiated coverage on GLMD last year, with a $20 price target.